An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans
Scott RA., Scott LJ., Mägi R., Marullo L., Gaulton KJ., Kaakinen M., Pervjakova N., Pers TH., Johnson AD., Eicher JD., Jackson AU., Ferreira T., Lee Y., Ma C., Steinthorsdottir V., Thorleifsson G., Qi L., Van Zuydam NR., Mahajan A., Chen H., Almgren P., Voight BF., Grallert H., Müller-Nurasyid M., Ried JS., Rayner NW., Robertson N., Karssen LC., van Leeuwen EM., Willems SM., Fuchsberger C., Kwan P., Teslovich TM., Chanda P., Li M., Lu Y., Dina C., Thuillier D., Yengo L., Jiang L., Sparso T., Kestler HA., Chheda H., Eisele L., Gustafsson S., Frånberg M., Strawbridge RJ., Benediktsson R., Hreidarsson AB., Kong A., Sigurðsson G., Kerrison ND., Luan J., Liang L., Meitinger T., Roden M., Thorand B., Esko T., Mihailov E., Fox C., Liu C-T., Rybin D., Isomaa B., Lyssenko V., Tuomi T., Couper DJ., Pankow JS., Grarup N., Have CT., Jørgensen ME., Jørgensen T., Linneberg A., Cornelis MC., van Dam RM., Hunter DJ., Kraft P., Sun Q., Edkins S., Owen KR., Perry JRB., Wood AR., Zeggini E., Tajes-Fernandes J., Abecasis GR., Bonnycastle LL., Chines PS., Stringham HM., Koistinen HA., Kinnunen L., Sennblad B., Mühleisen TW., Nöthen MM., Pechlivanis S., Baldassarre D., Gertow K., Humphries SE., Tremoli E., Klopp N., Meyer J., Steinbach G., Wennauer R., Eriksson JG., Mӓnnistö S., Peltonen L., Tikkanen E., Charpentier G., Eury E., Lobbens S., Gigante B., Leander K., McLeod O., Bottinger EP., Gottesman O., Ruderfer D., Blüher M., Kovacs P., Tonjes A., Maruthur NM., Scapoli C., Erbel R., Jöckel K-H., Moebus S., de Faire U., Hamsten A., Stumvoll M., Deloukas P., Donnelly PJ., Frayling TM., Hattersley AT., Ripatti S., Salomaa V., Pedersen NL., Boehm BO., Bergman RN., Collins FS., Mohlke KL., Tuomilehto J., Hansen T., Pedersen O., Barroso I., Lannfelt L., Ingelsson E., Lind L., Lindgren CM., Cauchi S., Froguel P., Loos RJF., Balkau B., Boeing H., Franks PW., Barricarte Gurrea A., Palli D., van der Schouw YT., Altshuler D., Groop LC., Langenberg C., Wareham NJ., Sijbrands E., van Duijn CM., Florez JC., Meigs JB., Boerwinkle E., Gieger C., Strauch K., Metspalu A., Morris AD., Palmer CNA., Hu FB., Thorsteinsdottir U., Stefansson K., Dupuis J., Morris AP., Boehnke M., McCarthy MI., Prokopenko I.
To characterize type 2 diabetes (T2D)-associated variation across the allele frequency spectrum, we conducted a meta-analysis of genome-wide association data from 26,676 T2D case and 132,532 control subjects of European ancestry after imputation using the 1000 Genomes multiethnic reference panel. Promising association signals were followed up in additional data sets (of 14,545 or 7,397 T2D case and 38,994 or 71,604 control subjects). We identified 13 novel T2D-associated loci (P < 5 × 10−8), including variants near the GLP2R, GIP, and HLA-DQA1 genes. Our analysis brought the total number of independent T2D associations to 128 distinct signals at 113 loci. Despite substantially increased sample size and more complete coverage of low-frequency variation, all novel associations were driven by common single nucleotide variants. Credible sets of potentially causal variants were generally larger than those based on imputation with earlier reference panels, consistent with resolution of causal signals to common risk haplotypes. Stratification of T2D-associated loci based on T2D-related quantitative trait associations revealed tissue-specific enrichment of regulatory annotations in pancreatic islet enhancers for loci influencing insulin secretion and in adipocytes, monocytes, and hepatocytes for insulin action–associated loci. These findings highlight the predominant role played by common variants of modest effect and the diversity of biological mechanisms influencing T2D pathophysiology.